Rubius Therapeutics is a biotechnology business based in the US. Rubius Therapeutics shares (RUBY) are listed on the PINK and all prices are listed in US Dollars. Rubius Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.06 |
|---|---|
| 52-week range | $0.02 - $0.06 |
| 50-day moving average | $0.02 |
| 200-day moving average | $0.02 |
| Wall St. target price | $1.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.99 |
Historical closes compared with the close of $0.057 from 2023-12-29
| 1 week (2024-07-13) | N/A |
|---|---|
| 1 month (2024-06-20) | N/A |
| 3 months (2024-04-20) | N/A |
| 6 months (2024-01-20) | N/A |
| 1 year (2023-07-24) | 185.00% |
|---|---|
| 2 years (2022-07-22) | -92.61% |
| 3 years (2021-07-23) | 21.77 |
| 5 years (2019-07-24) | 13.67 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -46.63% |
| Return on equity TTM | -185.31% |
| Profit margin | 0% |
| Book value | $0.17 |
| Market Capitalization | $5.2 million |
TTM: trailing 12 months
We're not expecting Rubius Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Rubius Therapeutics's shares have ranged in value from as little as $0.0161 up to $0.057. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Rubius Therapeutics's is 2.208. This would suggest that Rubius Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Rubius Therapeutics, Inc. , a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.